Subclassification Can Tailor Surveillance for Pancreatic Adenocarcinoma
By Elana Gotkine HealthDay Reporter
WEDNESDAY, April 17, 2024 -- Subclassification of individuals at high risk for pancreatic adenocarcinoma (PC) can enable the development of surveillance approaches better tailored to risk, according to a study published online April 16 in the Journal of the National Comprehensive Cancer Network.
George Zogopoulos, M.D., Ph.D., from McGill University Health Center in Montreal, and colleagues established a multi-institutional international collaboration, the Pancreatic Cancer Early Detection (PRECEDE) Consortium, to address the unmet clinical need for surveillance for high-risk individuals (HRIs). A total of 3,402 participants were enrolled in one of seven study cohorts from April 1, 2020, to Nov. 21, 2022; 51.7 percent met the criteria for the highest-risk cohort (cohort 1). Cohort 1 HRIs underwent germline testing and pancreas imaging.
A total of 1,400 participants in cohort 1 had completed baseline imaging and were classified into three groups based on familial PC (FPC; 670 participants); a pathogenic germline variant (PGV) and FPC (PGV+/FPC+; 115 participants); and a PGV with a pedigree that did not meet the criteria for FPC (PGV+/FPC−; 615 participants). The researchers found that on study entry, one HRI was diagnosed with stage IIB PC; 35.1 percent of HRIs harbored pancreatic cysts. Independent predictors of harboring a pancreatic cyst included older age (odds ratio, 1.05) and FPC group assignment (odds ratio, 1.57 relative to PGV+/FPC−).
"Our interim analysis suggests that classifying HRIs into FPC, PGV+/FPC+, and PGV+/FPC− risk groups may have biologic relevance with clinical significance for tailored surveillance of HRIs," the authors write. "We recommend that this subclassification of HRIs be adopted by surveillance protocols moving forward."
The study was funded by Ambry Genetics, TrovaNOW, Amazon Web Services, Project Purple, REALM IDx, and Invicro, through the PRECEDE Consortium.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted April 2024
Read this next
GPT IDs Errors in Reports With Same Accuracy as Radiologists
TUESDAY, April 30, 2024 -- GPT-4 detects errors in radiology reports with the same accuracy as that of radiologists, according to a study published online April 16 in...
Home Vision Tests Offer Limited Diagnostic Accuracy for Neovascular AMD
MONDAY, April 29, 2024 -- No home-monitoring vision test has the diagnostic accuracy of hospital eye service follow-up clinics to identify active neovascular age-related macular...
Pandemic Reignited Debate Regarding Physician's Obligation to Treat
MONDAY, April 29, 2024 -- There was a surge in ethics literature during COVID-19 advocating for the ethical acceptability of physicians refusing to treat, according to a study...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.